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Glucose excursion was assessed prior to and post hypoglycaemia to increase understanding of
hypoglycaemia incidence and recovery during hybrid closed-loop insulin delivery. We retrospec-
tively analysed data from 60 adults with type 1 diabetes who received, in a crossover randomized
design, day-and-night hybrid closed-loop insulin delivery and insulin pump therapy, the latter with
or without real-time continuous glucose monitoring. Over 4-week study periods, we identified
hypoglycaemic episodes, defined as sensor glucose <3.0 mmol/L, and analysed sensor glucose rel-
ative to the onset of hypoglycaemia. We identified 377 hypoglycaemic episodes during hybrid
closed-loop intervention vs 662 during control intervention (P < .001), with a predominant reduc-
tion of nocturnal hypoglycaemia. The slope of sensor glucose prior to hypoglycaemia was steeper
during closed-loop intervention than during control intervention (P < .01), while insulin delivery
was reduced (P < .01). During both day and night, participants recovered from hypoglycaemia fas-
ter when treated by closed-loop intervention. At 120 minutes post hypoglycaemia, sensor glucose
levels were higher during closed-loop intervention compared to the control period (P < .05).
In conclusion, closed-loop intervention reduces the risk of hypoglycaemia, particularly overnight,
with swift recovery from hypoglycaemia leading to higher 2-hour post-hypoglycaemia glucose
levels.
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1 | INTRODUCTION
In type 1 diabetes, hypoglycaemia is a major barrier to achieving
euglycaemia using modern tight glycaemic control strategies.1 It may
be accompanied by sweating, trembling and confusion, and may
require assistance from another person.2
Insulin pump therapy has been shown to reduce glycated haemo-
globin levels without increasing the risk of hypoglycaemia.3 Continu-
ous glucose monitoring also leads to improved glucose control and
reduces the risk of hypoglycaemia4 and severe hypoglycaemia in
adults with type 1 diabetes.5 Closed-loop glucose control, combining
insulin delivery with real-time glucose sensing to administer insulin in
a glucose-responsive fashion, further improves glucose control.6 How-
ever, hypoglycaemia continues to be of concern during closed-loop
insulin delivery. Detailed assessments of hypoglycaemia timing, inci-
dence and other characteristics during home use of closed-loop insulin
delivery are undocumented.
In the present analysis, we retrospectively assessed hypoglycae-
mic episodes from a large dataset comprising sensor glucose and insu-
lin delivery involving 60 adults with type 1 diabetes who participated
in a randomized crossover study contrasting day-and-night hybrid
closed-loop insulin delivery and sensor-augmented or conventional
pump therapy. We report data over 4-week intervention periods and
describe diurnal distribution of hypoglycaemia events and describe
glucose excursion and insulin delivery before, during and after hypo-
glycaemic episodes.
2 | METHODS
2.1 | Experimental data
We retrospectively analysed 4-week-long periods of sensor glucose
and insulin delivery data collected in 60 adults (27 from Cambridge,
UK; 22 from Graz, Austria; 11 from Profil, Germany) with type 1 diabe-
tes (31 male; mean age, 40.0 [11.2] years; mean BMI, 25.2
[3.8] kg/cm2; baseline HbA1c, 7.7 [0.9]%; duration of diabetes, 22.1
[10.4] years; total daily insulin, 0.57 [0.14] U/kg).7,8
Participants were randomly assigned to receive, in a crossover
randomized fashion, hybrid day-and-night closed-loop insulin delivery
and sensor-augmented (32 participants) or conventional (28 partici-
pants) pump therapy. The participants' pre-study rapid-acting insulin
analogue (aspart or lispro) was used during the study. Real-time
(closed-loop and sensor-augmented pump therapy) or masked (con-
ventional pump therapy) glucose levels were measured using a contin-
uous glucose monitoring device (FreeStyle Navigator II, Abbott
Diabetes Care, Alameda, California) calibrated according to the manu-
facturer's instructions. The built-in bolus wizard of the study insulin
pump (Dana Diabecare R, SOOIL, Seoul, Republic of Korea) was used
by participants to calculate insulin boluses at mealtimes and when
administering correction boluses. During the closed-loop period, a
model-predictive control algorithm directed basal insulin delivery.7,8
A hypoglycaemic episode was defined as sensor glucose
<3 mmol/L for at least 10 minutes.9 Hypoglycaemic episodes that
were at least 30 minutes apart were counted as separate events. We
excluded episodes within 60 minutes of insulin bolus as these epi-
sodes may be predominantly attributable to bolus over-delivery and
unrelated to closed-loop glucose control. The exclusion criterion was
applied to both study periods.
2.2 | Statistical analysis
We identified hypoglycaemic episodes for each participant separately.
We evaluated for each participant the average sensor glucose and the
average basal insulin infusion rates from −60 to 120 minutes in
10-minute steps relative to the onset of hypoglycaemic episodes. We
then calculated the mean sensor glucose excursions and mean basal
insulin infusion across all participants. The minimum glucose levels
during hypoglycaemia, the area-under-curve (AUC) hypoglycaemia
and the duration of hypoglycaemia were also calculated. Hypoglycae-
mic episodes identified during the night (midnight to 6:00 AM) and dur-
ing the day (6:00 AM to midnight) were analysed separately.
A Student's t-test contrasted endpoints collected during closed-
loop and control periods. Statistical analyses were performed using
SPSS, version 21 (IBM Software, Hampshire, UK). P values less than
.05 were considered statistically significant. Data are presented as
mean (SD) unless stated otherwise.
3 | RESULTS
Data from 1680 days of closed-loop insulin delivery and 1680 days of
sensor-augmented or conventional insulin pump therapy were ana-
lysed. We identified 377 hypoglycaemic episodes during the closed-
loop period, of which 87 were nocturnal (midnight to 6:00 AM), as
compared to 662 episodes during the control period, of which
205 were nocturnal (closed-loop vs control arm, 1.27 [1.17] vs 2.48
[2.50] episodes per participant per week; P < .001).
Figure 1 shows the diurnal distribution of hypoglycaemia inci-
dence during 2 treatment periods. A reduced incidence of hypoglycae-
mia was observed during the closed-loop period as compared to the
control period, with a predominant reduction between 10:00 PM and
8:00 AM when the incidence of hypoglycaemia was halved. Figure S1
shows the risk of hypoglycaemia conditioned on ambient sensor glu-
cose; with sensor glucose between 3 and 8 mmol/L, the risk of hypo-
glycaemia 60 minutes later is halved during closed-loop intervention.
Figure 2 summarizes sensor glucose levels before, during and
after hypoglycaemic episodes during closed-loop and control periods.
Sensor glucose prior to hypoglycaemia had a steeper decline during
closed-loop intervention as compared to the control period (P = .002).
During the day, participants recovered from hypoglycaemia more rap-
idly when treated by closed-loop intervention (higher sensor glucose
values from 20 to 120 minutes post hypoglycaemia; P < .05). A similar
trend was observed during the night. Table S1 shows sensor glucose
values from 30 to 120 minutes relative to the onset of
hypoglycaemia.
Mean basal insulin infusion rates were lower during closed-loop
intervention as compared to control periods, from −60 to 80 minutes
during the day (P = .001) and from −60 to 50 minutes during the day
(P = .003), respectively.
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Minimum glucose levels during hypoglycaemia did not differ
between closed-loop and open-loop intervention (2.4 [0.4] vs 2.5
[0.4] mmol/L; P = .4 for the night period and 2.6 [0.2] vs 2.5
[0.4] mmol/L; P = .1 for the day period). AUC hypoglycaemia was
reduced during closed-loop compared to open-loop intervention (40.3
[33.1] vs 52.8 [43.9] mmol/L min; P = .04 for the night period and 22.4
[8.8] vs 38.8 [52.9] mmol/L min; P = .02 for the day period). The dura-
tion of hypoglycaemia was reduced by 21 minutes during the closed-
loop night period (51.9 [30.3] vs 72.9 [37.8] minutes; P < .001), with no
difference during the day (35.2 [11.9] vs 45.5 [24.4] minutes; P = .06].
4 | DISCUSSION
The present analysis reports the incidence and diurnal distribution of
hypoglycaemia in adults with type 1 diabetes during home use of
hybrid closed-loop insulin delivery and sensor-augmented or conven-
tional insulin pump therapy. We evaluated sensor glucose excursions
and basal insulin infusion rates prior to and post hypoglycaemia. We
found different patterns of hypoglycaemia incidence and hypoglycae-
mia recovery between the 2 interventions.
Many prospective and retrospective studies of hypoglycaemia inci-
dence are based on self-reported data, with considerable variation in
reported outcomes (eg, 43 episodes per patient-year,10 73 episodes per
patient-year11 and 94 episodes per patient-year12). In the present anal-
ysis, we report the incidence of clinically significant hypoglycaemia at
144 episodes per patient-year during insulin pump therapy using sensor
glucose data. Continuous glucose monitoring provides comprehensive
glucose levels over 24 hours and enables transparent definition and
recording of hypoglycaemic episodes when device usage is high, as in
the present analysis with median sensor wear time at 94% and 95% of
the total time for closed-loop and control periods, respectively.
Our analyses document the risk of hypoglycaemia being reduced
during closed-loop compared to control periods (377 vs 662 hypogly-
caemic episodes) in adults with type 1 diabetes and with baseline
HbA1c levels ranging from 5.8% to 9.7%. Figure 1 shows that the pre-
dominant reduction in hypoglycaemia was during the night. Figure 2
shows that, during closed-loop periods, sensor glucose reduced more
rapidly prior to hypoglycaemia as compared to control intervention.
Our interpretation is that closed-loop intervention was capable of pre-
venting hypoglycaemia when sensor glucose was not decreasing rap-
idly. Thus, only a rapid decline in sensor glucose leads to
hypoglycaemia during closed-loop intervention. This is supported by
reducing the risk of hypoglycaemia within 60 minutes, stratified
according to ambient sensor glucose (Figure S1).
Two peaks of hypoglycaemia incidence were observed during
2 treatment periods, 1 at approximately 4:00–8:00 PM and the other at
approximately 12:00–2:00 AM (Figure 1). The former may be related to
increased physical activity and the latter may result from post-meal
insulin corrections because of delayed effects following high-fat eve-
ning meals.13
Previous studies have shown that closed-loop intervention
improves glycaemic control in type 1 diabetes through the system's
ability to adjust insulin delivery in response to varying insulin require-
ments.14 Figure 2 demonstrates this paradigm; comparing the mean
insulin delivery at approximately 0.8 U/h observed even during immi-
nent onset of hypoglycaemia, closed-loop intervention reduced insulin
delivery from −60 to 80 minutes relative to onset of overnight hypo-
glycaemia and from −60 to 50 minutes relative to daytime hypogly-
caemia. The reduced amount of insulin resulted in more rapid
recovery and higher 2-hour post-hypoglycaemia glucose levels during
closed-loop intervention (Table S1 and Figure 2).
Glucose troughs during hypoglycaemia did not differ during
closed-loop and open-loop interventions. However, during closed-
loop intervention, both AUC hypoglycaemia and the duration of hypo-
glycaemic events were reduced because of a more rapid recovery
from hypoglycaemia.
An observational study reported that, in real-life settings, a major-
ity of patients over treated their hypoglycaemic episodes.15 Given
that post-hypoglycaemia glucose levels were higher during closed-
loop intervention as compared to control periods, a reasonable recom-
mendation for clinical practitioners would be to reinforce, and possibly
revise, patient education concerning hypoglycaemia correction, espe-
cially for those undergoing closed-loop treatment. Further studies are
warranted to explore optimal strategies for hypoglycaemia treatment
during closed-loop glucose control.
The strengths of our analysis are the multicentre, multinational,
crossover, randomized study design, in which each subject serves as
his/her own control, and the considerable volume of sensor glucose
data used to identify the hypoglycaemic episodes. The data were col-
lected during unsupervised home studies and, thus, glucose excur-
sions reflect hypoglycaemia incidence and self-treatment of
hypoglycaemia under free-living settings. The limitations include the
lack of reliable data concerning the amount of rescue carbohydrates.
In conclusion, hybrid closed-loop intervention reduces the risk of
hypoglycaemia, particularly during the night, with a swift recovery
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FIGURE 1 Incidence of hypoglycaemia events (sensor glucose
<3.0 mmol/L for at least 10 minutes) during hybrid closed-loop insulin
delivery (dark grey bars) and control periods (light grey bars)
(mean; N = 60)
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from hypoglycaemia during the day, and leads to slightly elevated
2-hour post-hypoglycaemia glucose levels compared to those with
insulin pump therapy.
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(A)
(B)FIGURE 2 Sensor glucose values from
−60 to 120 minutes relative to the onset
of hypoglycaemia (sensor glucose
<3.0 mmol/L; vertical bar) during the
hybrid closed-loop period (circles
connected by solid line; mean  SEM;
N = 60; *P < .05, **P < .01 compared to
control therapy) and during the control
period (triangles connected by dashed
line). Piecewise-constant lines without
error bars represent mean insulin infusion
rates during the closed-loop period and
dashed lines without error bars represent
insulin infusions during the control period.
Panel A, shows glycaemic and insulin
infusion data during the night period
(midnight to 6:00 AM) and panel B, shows
the day period (6:00 AM to midnight)
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